Skip to main content
Clinical Trials/JPRN-jRCT2080221820
JPRN-jRCT2080221820
Unknown
Phase 3

A Long-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Autistic Disorder, Children and Adolescents
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 7, 2012
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) The patient meets Autistic disorder diagnostic criteria defined in DSM\-IV\-TR.
  • 2\) The patient has completed the 031\-11\-002 study (the patient has visited the hospital during week8\)
  • 3\) Inpatient or outpatient status
  • 4\) Othress

Exclusion Criteria

  • 1\) The patient is currently diagnosed with another disorder on the autism spectrum in DSMIV\-TR, including Asperger's, Rett's Disorder, PDD\-NOS, Childhood Disintegrative Disorder, or Fragile\-X Syndrome.
  • 2\) Patients who fall under a contraindication listed in the ABILIFY package insert

Outcomes

Primary Outcomes

Not specified

Similar Trials